Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

J Thromb Thrombolysis. 1999 Jun;7(3):277-85. doi: 10.1023/a:1008983110941.

Abstract

During recent years it has become increasingly recognized that the plasmin activation system is involved in the development of atherosclerosis and restenosis. Responsible pathophysiologic mechanisms, however, remain elusive. This review focuses primarily on the clinicians, point of view, suggesting that increases in plasminogen activator inhibitor type-1 (PAI-1) plasma levels after balloon angioplasty or permanently elevated lipoprotein (a) (Lp(a)) plasma levels might be helpful in the prediction of restenosis after coronary angioplasty. In contrast, tissue-type plasminogen activator (tPA) plasma levels appear unrelated to restenosis, and data regarding a possible role of urokinase-type plasminogen activator (uPA) in circulation are not available at present. Furthermore, a new hypothesis on the pathophysiological role of local PAI-1 overexpression as a beneficial negative feedback mechanism to limit excess cellular proliferation in atherogenesis and restenosis is presented.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary
  • Biomarkers
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / pathology
  • Coronary Disease / blood*
  • Coronary Disease / therapy
  • Disease Progression
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / pathology
  • Fibrinolysin / biosynthesis*
  • Humans
  • Hyperplasia
  • Lipoprotein(a) / blood*
  • Plasminogen Activator Inhibitor 1 / blood*
  • Plasminogen Activator Inhibitor 1 / physiology
  • Postoperative Period
  • Predictive Value of Tests
  • Recurrence
  • Tissue Plasminogen Activator / blood
  • Tunica Intima / metabolism
  • Tunica Intima / pathology
  • Urokinase-Type Plasminogen Activator / blood
  • Wound Healing

Substances

  • Biomarkers
  • Lipoprotein(a)
  • Plasminogen Activator Inhibitor 1
  • Tissue Plasminogen Activator
  • Fibrinolysin
  • Urokinase-Type Plasminogen Activator